Interleukin 6 and complement serum level study in Parkinson's disease
Jazyk angličtina Země Rakousko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
29435648
DOI
10.1007/s00702-018-1857-5
PII: 10.1007/s00702-018-1857-5
Knihovny.cz E-zdroje
- Klíčová slova
- Complement, Interleukin 6, Parkinson’s disease,
- MeSH
- biologické markery krev MeSH
- interleukin-6 krev MeSH
- komplement 4 analýza MeSH
- komplement C3 analýza MeSH
- lidé středního věku MeSH
- lidé MeSH
- longitudinální studie MeSH
- Parkinsonova nemoc krev imunologie MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- biologické markery MeSH
- IL6 protein, human MeSH Prohlížeč
- interleukin-6 MeSH
- komplement 4 MeSH
- komplement C3 MeSH
The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.
Zobrazit více v PubMed
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed
Neurology. 1967 May;17(5):427-42 PubMed
Int Immunol. 2015 Jan;27(1):21-9 PubMed
J Neurol. 2010 Apr;257(4):524-32 PubMed
Parkinsonism Relat Disord. 2009 May;15(4):318-20 PubMed
Parkinsonism Relat Disord. 2015 Oct;21(10 ):1219-26 PubMed
Ann N Y Acad Sci. 2009 Feb;1153:220-39 PubMed
Brain Behav Immun. 2013 Oct;33:183-9 PubMed
Eur J Neurol. 2009 Jan;16(1):142-7 PubMed
Neurochem Res. 2009 Aug;34(8):1401-4 PubMed
Clin Neurosci Res. 2006 Aug;6(1-2):52-68 PubMed
PLoS One. 2012;7(10):e47387 PubMed
Arch Neurol. 2003 Aug;60(8):1059-64 PubMed
Curr Opin Pharmacol. 2016 Feb;26:87-95 PubMed
Neurosci Lett. 2008 Aug 22;441(2):158-62 PubMed
PLoS One. 2015 Aug 26;10(8):e0136722 PubMed
Neurosci Lett. 1996 Jun 14;211(1):13-6 PubMed
Mov Disord. 2016 Jul;31(7):995-1003 PubMed
Md State Med J. 1965 Feb;14:61-5 PubMed
Nat Rev Neurosci. 2008 Jan;9(1):46-56 PubMed
J Psychiatr Res. 1975 Nov;12(3):189-98 PubMed
Br J Psychiatry. 1979 Apr;134:382-9 PubMed
Neurosci Lett. 2010 Jan 1;468(1):56-8 PubMed
Acta Neurol Scand. 1998 Aug;98(2):142-4 PubMed
Mol Immunol. 2007 Feb;44(5):999-1010 PubMed
Neurosci Lett. 1994 Oct 24;180(2):147-50 PubMed
Gerontologist. 1969 Autumn;9(3):179-86 PubMed
JAMA Neurol. 2016 Nov 1;73(11):1316-1324 PubMed
Dis Markers. 2005;21(2):93-101 PubMed
Acta Neurol Scand. 1999 Jul;100(1):34-41 PubMed
Acta Neuropathol. 1992;84(1):100-4 PubMed
Parkinsons Dis. 2015;2015:898192 PubMed
Brain Res. 1996 Jan 29;707(2):196-205 PubMed
